🛡️ Hazard Overview
- GHS Class: GHS06; GHS07; GHS08; GHS09
- Signal Word: Danger
- Hazard Statements: H301; H302; H361; H372; H411
🧤 PPE Guidelines
- Gloves: Chemical‑resistant gloves suggested
- Eye Protection: Safety goggles suggested
- Respirator: Dust respirator if dust occurs
❄️ Storage
- Storage Temp: -20°C (-4°F) Keep dry
🚑 Emergency First Aid
- For inhalation, skin, eye or ingestion exposure, please refer to full SDS Section 4.
Product identifier
- Product Name: Diclofenac acid
- Catalog Number: S6073
- CAS Number: 15307-86-5
- IUPAC Name: Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-
Relevant identified uses and uses advised against
- Identified uses: For research and development use only; laboratory chemicals; manufacture of substances.
- Uses advised against: Not for pharmaceutical, household, or other unapproved uses.
Details of the supplier
- Company: Selleck Chemicals
- TollFree: +1 877 796-6397
- Tel: +1 832 582-8158
- Fax: +1 832 582-8590
Emergency telephone number
- Emergency phone #: +1 832 582-8158
2.1 GHS classification in accordance with 29 CFR 1910 (OSHA HCS):
Acute toxicity (oral): Category 3. H301
Acute toxicity (oral): Category 4. H302
Reproductive toxicity: Category 2. H361
Specific target organ toxicity (repeated exposure): Category 1. H372
Chronic aquatic toxicity: Category 2. H411
2.2 GHS Label elements, including precautionary statements
Hazard Pictogram(s):
Signal Word:
Danger
Hazard statement(s):
H301: Toxic if swallowed
H302: Harmful if swallowed
H361: Suspected of damaging fertility or the unborn child
H372: Causes damage to organs through prolonged or repeated exposure
H411: Toxic to aquatic life with long lasting effects
Precautionary statement(s):
Prevention:
P203: Obtain, read and follow all safety instructions before use.
P260: Do not breathe dust/fume/gas/mist/vapors/spray.
P264: Wash hands thoroughly after handling.
P270: Do not eat, drink or smoke when using this product.
P273: Avoid release to the environment.
P280: Wear protective gloves/protective clothing/eye protection/face protection/hearing protection.
Response:
P301+P316: IF SWALLOWED: Get emergency medical help immediately.
P301+P317: IF SWALLOWED: Get medical help.
P318: if exposed or concerned, get medical advice.
P319: Get medical help if you feel unwell.
P321: Specific treatment (see information on this label and safety datasheet)).
P330: Rinse mouth.
P391: Collect spillage.
Storage:
P405: Store locked up.
Disposal:
P501: P501 Dispose of contents/ container to an approved waste disposal plant.
2.3 Other hazards
None.
3.1 Substances
Product name: Diclofenac acid
CAS Number: 15307-86-5
PubChem CID: 3033
Molecular formula: C14H11Cl2NO2
Molecular weight: 296.1 g/mol
IUPAC name: 2-[2-(2,6-dichloroanilino)phenyl]acetic acid
3.2 Mixtures
Not applicable (pure substance).
4.1 Description of first aid measures
Inhalation: Move to fresh air. Keep at rest in a position comfortable for breathing. Seek medical attention if symptoms persist.
Skin contact: Wash with plenty of soap and water. Remove contaminated clothing. Seek medical attention if irritation develops.
Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do. Continue rinsing. Seek medical attention.
Ingestion: Rinse mouth. Do NOT induce vomiting unless directed by medical personnel. Seek medical attention.
4.2 Most important symptoms and effects, both acute and delayed
See Section 11 (Toxicological Information).
4.3 Indication of any immediate medical attention and special treatment needed
Treat symptomatically. Contact a poison control center or physician for severe exposure.
5.1 Extinguishing media
Suitable: Water spray, dry chemical, carbon dioxide (CO2), alcohol-resistant foam.
Unsuitable: None known.
5.2 Specific hazards arising from the substance or mixture
Combustible. Heating may produce toxic fumes.
5.3 Advice for firefighters
Wear self-contained breathing apparatus (SCBA) and full protective clothing.
Fight fire from upwind. Cool containers with water spray until fire is extinguished.
6.1 Personal precautions, protective equipment and emergency procedures
Wear appropriate personal protective equipment (see Section 8).
Avoid breathing dust/vapor. Ensure adequate ventilation.
Evacuate personnel to safe areas. Keep people away from and upwind of spill.
WARNING: Highly toxic — only trained personnel should handle spills.
6.2 Environmental precautions
Prevent product from entering drains, waterways, or soil.
Contain spill with inert absorbent material.
6.3 Methods and materials for containment and cleaning up
SRP: Expired or waste pharmaceuticals shall carefully take into consideration applicable DEA, EPA, and FDA regulations. It is not appropriate to dispose by flushing the pharmaceutical down the toilet or discarding to trash. If possible return the pharmaceutical to the manufacturer for proper disposal being careful to properly label and securely package the material. Alternatively, the waste pharmaceutical shall be labeled, securely packaged and transported by a state licensed medical waste contractor to dispose by burial in a licensed hazardous or toxic waste landfill or incinerator.
SRP: At the time of review, regulatory criteria for small quantity disposal are subject to significant revision, however, household quantities of waste pharmaceuticals may be managed as follows: Mix with wet cat litter or coffee grounds, double bag in plastic, discard in trash.
7.1 Precautions for safe handling
Diclofenac sodium 1% gel and diclofenac epolamine transdermal system should be stored at 25 °C but may be exposed to temperatures ranging from 15-30 °C. Diclofenac gel should not be frozen.
Diclofenac sodium delayed-release (enteric-coated) tablets, diclofenac sodium extended-release tablets, and diclofenac potassium tablets should be protected from moisture and stored in tight containers at a temperature not exceeding 30 °C. Commercially available diclofenac sodium and misoprostol tablets should be stored in a dry area at a temperature not exceeding 25 °C.
7.2 Conditions for safe storage, including any incompatibilities
Diclofenac sodium 1% gel and diclofenac epolamine transdermal system should be stored at 25 °C but may be exposed to temperatures ranging from 15-30 °C. Diclofenac gel should not be frozen.
Diclofenac sodium delayed-release (enteric-coated) tablets, diclofenac sodium extended-release tablets, and diclofenac potassium tablets should be protected from moisture and stored in tight containers at a temperature not exceeding 30 °C. Commercially available diclofenac sodium and misoprostol tablets should be stored in a dry area at a temperature not exceeding 25 °C.
Store away from incompatible materials (see Section 10).
[Note: Specific storage temperature not available in public databases. Refer to supplier Certificate of Analysis (COA) for exact storage conditions.]
8.1 Exposure controls
8.1.1 Occupational exposure limits (OEL)
OSHA PEL: Not established.
ACGIH TLV: Not established.
NIOSH REL: Not established.
No occupational exposure limit values are established for this substance.
Use the lowest feasible exposure level (ALARA principle).
8.1.2 Appropriate engineering controls
Use in a well-ventilated area. Chemical fume hood recommended for powder handling.
8.2 Individual protection measures
8.2.1 Eye/face protection
Wear safety glasses with side shields.
8.2.2 Skin protection
Wear protective gloves. Recommended material: Nitrile rubber.
Wear suitable protective clothing (lab coat).
8.2.3 Respiratory protection
Respiratory protection usually not required under normal use with adequate ventilation.
Use N95 respirator for large-scale powder handling.
8.2.4 Thermal hazards
Not applicable.
9.1 Information on basic physical and chemical properties
a) Appearance: Solid
b) Odor: No data available
c) Odor threshold: No data available
d) pH: No data available
e) Melting point/freezing point: 283-285 °C
f) Initial boiling point and boiling range: No data available
g) Flash point: No data available
h) Evaporation rate: No data available
i) Flammability (solid, gas): No data available
j) Upper/lower flammability or explosive limits: No data available
k) Vapor pressure: No data available
l) Vapor density: No data available
m) Relative density: No data available
n) Water solubility: In water, 2.37 mg/L at 25 °C
o) Partition coefficient: n-octanol/water: Log P (n-octanol/water): 4.4
p) Auto-ignition temperature: No data available
q) Decomposition temperature: No data available
r) Viscosity: No data available
s) Explosive properties: No data available
t) Oxidizing properties: No data available
9.2 Other information
Topological Polar Surface Area (TPSA): 49.3 Ų
Complexity: 304
10.1 Reactivity
No specific reactivity hazards identified under normal handling conditions.
10.2 Chemical stability
Stable under recommended storage conditions.
10.3 Possibility of hazardous reactions
No hazardous reactions under normal conditions.
10.4 Conditions to avoid
Avoid heat, sparks, open flames, direct sunlight, and moisture.
Avoid strong oxidizing agents, strong acids, and strong bases.
10.5 Incompatible materials
Strong oxidizing agents, strong acids, strong bases.
10.6 Hazardous decomposition products
Thermal decomposition may produce: Carbon monoxide (CO), Carbon dioxide (CO₂), Nitrogen oxides (NOx), Hydrogen chloride (HCl).
See also Section 5 (Fire-fighting measures) for combustion products.
11.1 Information on toxicological effects
Acute toxicity:
No acute toxicity data available.
Skin corrosion/irritation:
No data available.
Serious eye damage/eye irritation:
No data available.
Respiratory or skin sensitization:
No data available.
Germ cell mutagenicity:
No data available.
Carcinogenicity:
No data available.
Reproductive toxicity:
Suspected of damaging fertility or the unborn child (H361).
Specific target organ toxicity (single exposure):
H372
Specific target organ toxicity (repeated exposure):
No data available.
Aspiration hazard:
No data available.
11.2 Additional information
Carcinogen classification:
No indication of carcinogenicity to humans (not listed by IARC).
Exposure routes:
Completely absorbed from the gastrointestinal tract.
Signs and symptoms of exposure:
Symptoms of overdose include loss of consciousness, increased intracranial pressure, and aspiration pneumonitis.
Data source: Hazardous Substances Data Bank (HSDB) via PubChem.
12.1 Toxicity
/BIRDS and MAMMALS/ The nonsteroidal anti-inflammatory drug diclofenac is extremely toxic to Old World Gyps vultures (median lethal dose ~0.1-0.2 mg/kg), evoking visceral gout, renal necrosis, and mortality within a few days of exposure. Unintentional secondary poisoning of vultures that fed upon carcasses of diclofenac-treated livestock decimated populations in the Indian subcontinent. Because of the widespread use of diclofenac and other cyclooxygenase-2 inhibiting drugs, a toxicological study was undertaken in turkey vultures (Cathartes aura) as an initial step in examining sensitivity of New World scavenging birds. Two trials were conducted entailing oral gavage of diclofenac at doses ranging from 0.08 to 25 mg/kg body weight. Birds were observed for 7 days, blood samples were collected for plasma chemistry (predose and 12, 24, and 48 hr and 7 days postdose), and select individuals were necropsied. Diclofenac failed to evoke overt signs of toxicity, visceral gout, renal necrosis, or elevate plasma uric acid at concentrations greater than 100 times the estimated median lethal dose reported for Gyps vultures. For turkey vultures receiving 8 or 25 mg/kg, the plasma half-life of diclofenac was estimated to be 6 hr, and it was apparently cleared after several days as no residues were detectable in liver or kidney at necropsy. Differential sensitivity among avian species is a hallmark of cyclooxygenase-2 inhibitors, and despite the tolerance of turkey vultures to diclofenac, ad
12.2 Persistence and degradability
No data available.
12.3 Bioaccumulative potential
Log P (n-octanol/water): 4.4
Potential for bioaccumulation exists (Log P > 3).
12.4 Mobility in soil
No data available.
12.5 Results of PBT and vPvB assessment
PBT/vPvB assessment not available.
12.6 Other adverse effects
This substance is classified as hazardous to the aquatic environment.
13.1 Waste treatment methods
Waste Treatment Methods: Waste material must be disposed of in accordance with national and local regulations. Leave chemicals in original containers and do not mix with other waste. Handle uncleaned containers in the same manner as the product itself.
14.1 UN number
Not regulated as dangerous goods (research quantities typically exempt).
14.2 UN proper shipping name
Not subject to transport regulations (small quantities for research use).
14.3 Transport hazard class(es)
Not classified as dangerous goods for transport (research quantities).
14.4 Packing group
Not applicable (not regulated as dangerous goods in typical research quantities).
14.5 Environmental hazards
Marine pollutant: Yes (classified as environmentally hazardous per GHS).
14.6 Special precautions for user
Transport in original packaging. Ensure containers are tightly sealed.
For bulk or commercial quantities, consult applicable transport regulations (DOT, IATA, IMDG).
14.7 Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable.
15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture
US EPA / TSCA: Not available in public databases.
EU ECHA / REACH: Registered (REACH Active)
SARA 302 Components:
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.
SARA 313 Components:
This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.
SARA 311/312 Hazards:
Acute (short-term) health hazard
Chronic (long-term) health hazard
Environmental hazard
Massachusetts Right To Know Components:
This material contains components subject to the Massachusetts Right to Know Act. See Section 2 for hazard classification.
Pennsylvania Right To Know Components:
This material contains components subject to the Pennsylvania Right to Know Act. See Section 2 for hazard classification.
New Jersey Right To Know Components:
This material contains components subject to the New Jersey Right to Know Act. See Section 2 for hazard classification.
California Prop. 65 Components:
This product does not contain any chemicals known to the State of California to cause cancer, birth defects, or any other reproductive harm.
Other regulatory listings:
- FDA Requirements: Indications for use in horses: For the control of pain and inflammation associated with osteoarthritis in tarsal, carpal, metacarpophalangeal, metatarsophalangeal, and proximal interphalangeal (hock, knee, fetlock and pastern) joints. ... Limitations: Do not use in horses intended for human consumpt
15.2 Chemical safety assessment
A chemical safety assessment has not been carried out for this substance.
For research-use-only compounds, no CSA is required under REACH Annex I.
Revision Date: 2026/09/09
Further Information: The information provided is believed to be correct but is not exhaustive and should be used only as a guideline based on current knowledge. It does not represent a guarantee of the properties of the product. Selleck Chemicals Corporation and its Affiliates shall not be held liable for any damage resulting from handling or contact with the product.